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Background: Although neonatal infections cause a significant proportion of deaths in the first week of life, little is
known about the burden of neonatal disease originating from maternal infection or colonization globally. This
paper describes the prevalence of vertical transmission – the percentage of newborns with neonatal infection
among newborns exposed to maternal infection.
Methods: We searched Pubmed, Embase, Scopus, Web of Science, Cochrane Library, and WHO Regional Databases
for studies of maternal infection, vertical transmission, and neonatal infection. Studies that measured prevalence of
bacterial vertical transmission were included. Random effects meta-analyses were used to pool data to calculate
prevalence estimates of vertical transmission.
Results: 122 studies met the inclusion criteria. Only seven studies (5.7%) were from very high neonatal mortality
settings. Considerable heterogeneity existed between studies given the various definitions of infection (lab-confirmed,
clinical signs), colonization, and risk factors of infection. The prevalence of early onset neonatal lab-confirmed infection
among newborns of mothers with lab-confirmed infection was 17.2% (95%CI 6.5-27.9). The prevalence of neonatal
lab-confirmed infection among newborns of colonized mothers was 0% (95% CI 0.0-0.0). The prevalence of neonatal
surface colonization among newborns of colonized mothers ranged from 30.9-45.5% depending on the organism.
The prevalence of neonatal lab-confirmed infection among newborns of mothers with risk factors (premature rupture
of membranes, preterm premature rupture of membranes, prolonged rupture of membranes) ranged from 2.9-19.2%
depending on the risk factor.
Conclusions: The prevalence of early-onset neonatal infection is high among newborns of mothers with infection
or risk factors for infection. More high quality studies are needed particularly in high neonatal mortality settings to
accurately estimate the prevalence of early-onset infection among newborns at risk.
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Neonatal infections account for a significant proportion
of neonatal deaths in the first week of life [1]. In sub-
Saharan Africa, south Asia, and Latin America where
neonatal infections are most prevalent, the case fatality
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unless otherwise stated.in the first month of life is 9.8% [2]. Infections are one
of the three major causes of neonatal mortality and
account for approximately a quarter of newborn deaths
in the first month of life [3]. Neonatal infections are
acquired horizontally (from the environment) or vertically
(from mother). Not much is known about the routes of
transmission globally where different environments and
risk factors may affect paths of transmission. In resource-
rich settings, interventions such as intrapartum antibiotic
prophylaxis for high risk women has been effective inhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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contrast, these interventions are rare or absent in
resource-poor settings, which have the highest rates of
neonatal mortality. To develop research priorities and
strategies for prevention, we need to better understand
the prevalence of neonatal infections that are maternally
acquired. In this systematic review and meta-analysis, we
estimate the prevalence of early-onset neonatal infection
in cases where the pregnant woman was infected or
colonized with bacterial pathogens (hereafter referred to
“vertical transmission”) to better understand the global
rates of vertical transmission. We used a relaxed inclusion
criteria to include studies that at minimum measured
maternal infections and neonatal infections without




Although laboratory confirmed infections are considered
the gold standard measure of infection, the limited num-
ber of studies in African, eastern Mediterranean, and
southeast Asian regions with laboratory capabilities
would underestimate the prevalence of neonatal sepsis
among pregnant women who were infected or colonized.
Rather than restricting to only lab-confirmed definitions,
we also included clinical signs, colonization, and risk fac-
tors for infection (maternal only) to best estimate the
prevalence of vertical transmission. We specified these
definitions, our methods of analysis, and our inclusion
criteria in a protocol a priori.
We defined our exposure, maternal infection or
colonization during labor, in three categories:
(i) Maternal Infection
– Laboratory confirmed bacterial infection
(hereafter referred to as “lab”): culture or PCR
confirmed bacteremia, amnionitis, urinary tract
infections, chorioamnionitis;
– Clinical signs of infection (hereafter referred to as
“signs”): intrapartum maternal fever, uterine
tenderness, maternal tachycardia, malodorous
vaginal discharge, elevated white cell count,
elevated c-reactive protein, physician diagnosis of
clinical chorioamnionitis using a combination of
the above signs, or clinical infection undefined.
(ii) Maternal Colonization: positive reproductive tract/
genital bacterial cultures without signs or symptoms
of infection.
(iii) Risk factors for infection: premature rupture of
membranes (PROM - rupture of membranes prior
to onset of labor ≥ 37 weeks gestation), preterm
premature rupture of membranes (PPROM - rupture
of membranes prior to onset of labor < 37 weeksgestation), and prolonged rupture of membranes
(duration of rupture of membranes [ROM] ≥ 18-24
hours or undefined).
The outcome, early-onset neonatal infection or colon-
ization during the first seven days of life, was defined in
two categories:
(i) Neonatal Infection
– Laboratory confirmed bacterial infection (“lab”):
bacteremia, meningitis, urinary tract infection
(positive culture of blood, cerebral spinal fluid,
or urine);
– Clinical signs of infection (“signs”): pneumonia,
fever, hypothermia, respiratory distress,
bradycardia, tachycardia, irritability, lethargy,
hypotonia, seizures, poor feeding, oxygen
requirement, increased frequency of apnea, poor
capillary refill, metabolic acidosis, elevated white
cell count, high immature to total neutrophil
ratio, elevated c-reactive protein, or physician
diagnosis of clinical sepsis using a combination of
the above signs;
– Laboratory or clinical infection (hereafter referred
to as “lab/lab&signs”): a combination of either
laboratory confirmed infection or clinical signs of
infection, or undefined.
(ii) Newborn Colonization: positive ear canal, umbilical,
axilla, or anal cultures without signs or symptoms of
infection.
We use the term “maternal exposure” as an overarch-
ing description of exposures and “neonatal outcome” to
describe the outcomes.
Search strategy and section criteria
We searched Pubmed (Medline), Embase, Scopus, Web
of Science, the Cochrane Library, and the World Health
Organization (WHO) Regional Databases. A comprehen-
sive search strategy was developed with three concepts:
maternal infection, vertical transmission, and neonatal
infection (Additional file 1: Table S1). We performed
final searches of databases on February 20, 2012 with no
date restrictions. We downloaded and reviewed articles
using EndNote (version X4). Hand-searches through the
reference lists of screened articles and published system-
atic reviews did not produce any additional articles.
Source articles included publications, abstracts, and con-
ference proceedings available in the public domain.
We included studies of any design that measured the
prevalence or incidence (assumed to be period prevalence)
of bacterial vertical transmission, or contained raw data to
calculate these measures, even if vertical transmission was
not the main aim of the study. To be included, studies
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of maternal exposures and a measure of neonatal out-
comes, and be written in English. We excluded studies if:
the sample size was less than ten; all subjects (pregnant
women) received antibiotics or steroids; or data related to
nonbacterial infections, tetanus infections, or sexually
transmitted infections such as chlamydia and syphilis,
which have different mechanisms of transmission.
Screening and data abstraction
Two reviewers independently screened titles, abstracts,
and articles using predetermined selection criteria and
standardized data abstraction forms. Two data abstrac-
tors independently gathered data from included studies
to assess risk of bias, classify exposures and outcomes,
determine the number of newborns in each exposure-
outcome category, and calculate a prevalence measure.
One reviewer abstracted study characteristics data. To
improve data quality, a second reviewer abstracted study
characteristics for a random 10% of the studies. At each
stage, the reviewers compared their results and resolved
disagreements by reaching a consensus. For articles miss-
ing information critical to our analysis, we contacted the
authors to request the missing data.
We obtained basic data on author, country, study
design, sample size, and study setting: (1) health facility,
multi-center, or community-based, and (2) urban versus
rural. The studies provided limited data on intrapartum
antibiotic use; we categorized studies based on whether
they had no intrapartum antibiotic use, some antibiotic
use, or unknown if the study did not report antibiotic
use. We defined our outcome, early-onset neonatal in-
fection, to the first seven days of life. Studies that used
the term “early-onset neonatal sepsis” but did not specify
timing (i.e. seven days or three days) were also included.
We also included studies that examined only high risk
populations such as preterm labor, PROM, PPROM, and
prolonged rupture of membranes. To assess for varia-
tions by region, we grouped studies by World Health
Organization region, 2010 World Bank gross national
income per capita in US dollars (low $1005 or less,
lower-middle $1006-3975, upper-middle $3976-12 275,
high income $12 276 or more), and 2009 UNICEF neo-
natal mortality rates (very low <5 deaths per 1000 live
births, low 5-14 deaths/1000, high 15-27 deaths/1000,
and very high more than 27 deaths/1000) [4-6].
Two independent reviewers assessed the methodological
quality of included studies, examining selection methods,
missing data, loss-to-follow-up, misclassification or meas-
urement errors of exposures or outcomes, and confound-
ing bias. Biases in selection and misclassification would
have the largest effect on prevalence results. Studies were
given an overall rating of low risk of bias if both selection
and misclassification biases were at low risk. Studies thatwere high risk for either selection or misclassification bias
or both were rated as high risk of bias. Studies that did
not meet the low or high risk criteria were rated as having
unclear risk of bias.
Statistical analysis
We used random-effects meta-analyses to calculate
weighted mean estimates across studies and the 95% CI
for the point prevalence of vertical transmission (Stata
v12). If raw data were not available, we used the reported
vertical transmission prevalence and calculated the stand-
ard error SE = √ [p(1 - p)/n]. If there were two or more
studies included in the meta-analysis, we assessed mea-
sures of heterogeneity with I2 statistics. For each combin-
ation of maternal exposure and neonatal outcome, we
calculated a pooled estimate of the prevalences. Because
of the substantial heterogeneity across all combinations of
maternal exposures and neonatal outcomes, we did not
calculate an overall pooled estimate of the prevalences.
The studies we examined used numerous combina-
tions of maternal exposure and neonatal outcome. This
paper presents the following combinations:
i) maternal lab confirmed infection and neonatal lab
confirmed infection (lab/lab);
ii) maternal lab confirmed infection and neonatal
clinical signs of infection (lab/signs);
iii)maternal lab confirmed infection and neonatal lab or
clinical infection (lab/lab&signs);
iv)maternal clinical signs of infection and neonatal lab
confirmed infection (signs/lab);
v) maternal clinical signs of infection and neonatal
clinical signs of infection (signs/signs);
vi)maternal clinical signs of infection and neonatal lab
or clinical infection (signs/lab&signs);
vii) maternal colonization and neonatal lab confirmed
infection (colonization/lab);
viii) maternal colonization and neonatal clinical signs of
infection (colonization/signs);
ix) maternal colonization and neonatal lab or clinical
infection (colonization/lab&signs);
x) maternal colonization and neonatal colonization
(colonization/colonization);
xi)maternal risk factor and neonatal lab confirmed
infection (risk/lab);
xii) maternal risk factor and neonatal clinical signs of
infection (risk/signs).The four forest plots presented in this paper estimate
the vertical transmission point prevalence, 95% CI, and
relative weights for four different groupings of these com-
binations: (i-vi) maternal infection and neonatal infection;
(vii-ix) maternal colonization and neonatal infection; (x)
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(xi-xii) maternal risk factors and neonatal infections.
We originally planned for subgroup analyses by region,
gross national income per capita in US dollars stratum,
intrapartum antibiotic use, and neonatal mortality rate
stratum. However, given the scarcity of data in the lower
income and higher mortality rates countries, we were only
able to describe the distribution of studies by region,
income, and neonatal mortality rate. For the maternal
colonization and neonatal colonization analysis, we exam-
ined pathogen-specific subgroups with Staphylococcus
aureus, non-group B Streptococcus species, Group B
streptococcus, Klebsiella pneumoniae, Escherichia coli,
Ureaplasma species, Mycoplasma hominis, and multiple
organisms. In our sensitivity analyses, we repeated meta-
analyses excluding studies with (i) some or unknown
intrapartum antibiotics use to understand the natural his-
tory of vertical transmission in settings of most LIC where
intrapartum antibiotics are not available and (ii) high risk
of bias. We planned these subgroup and sensitivity ana-
lyses a priori.
Role of the funding source
The funding source had no role in the study design,
data collection, analysis, interpretation, or writing of
the report. The corresponding author had full access to
all the data in the study and had final responsibility for
the decision to submit the publication.
Results
Our search identified 4436 articles of which 3486 were
unique records. We reviewed 331 full-text articles. Eight-
een authors were contacted regarding missing data and
provided with a sample 2×2 table to complete. One [7]
out of the four authors who responded provided usable
data. Data from 122 studies met the inclusion criteria.
Our qualitative analysis included all 122 studies; our quan-
titative meta-analysis included 107 of them (Figure 1,
Additional file 2: Table S2). The majority of studies used
cohort designs (n = 117, 95.9%) set in single health facil-
ities (n = 94, 77.0%). In 75 studies (61.5%), researchers
measured early-onset neonatal infection during the first
seven days of life. Twenty-eight studies (23.0%) had
data on women who did not use intrapartum antibiotics
(either the study cohort did not use antibiotics, the
study excluded women who received antibiotics, or data
were abstracted from the placebo arm of an interven-
tion trial); 51 studies (41.8%) reported some antibiotic
use in a subset of women for prophylaxis or treatment;
and 43 studies (35.2%) did not specify whether antibiotics
were used. A sensitivity analysis around studies without
or unknown use of antibiotics was limited by the data
available and only possible in the subgroup maternal
colonization and neonatal infection.Thirty eight of the studies (31.1%) restricted their
enrolment to a specific subset of women (preterm labor,
PROM, PPROM, prolonged rupture), while a majority of
studies (n = 80, 65.6%) examined all pregnant women.
Four studies (3.3%) did not report the inclusion or
exclusion criteria. Most studies (n = 101, 82.8%) oc-
curred in the Americas or Europe, ten studies (8.2%)
were in the western Pacific, five studies (4.1%) were in
southeast Asia, three studies (2.5%) were in the eastern
Mediterranean region, and three studies (2.5%) were in
Africa. Most studies (n = 104, 85.2%) were in high
income and low mortality settings (Table 1). Table 1
describes the number of studies and study characteristics
in each meta-analysis. A study could report more than
one maternal condition but was used only once in each
meta-analysis (Additional file 3: Table S3, Additional
file 4: Table S4).
Using available data from this pool of studies, we cal-
culated the following median prevalence of exposures
and outcomes: maternal lab-confirmed infection (17
studies, median prevalence 24.0%, interquartile range
[IQR] 10.0-28.3), maternal clinical signs of infection (8
studies, median prevalence 11.6%, IQR 2.7-15.6), maternal
colonization (60 studies, median prevalence 16.3%, IQR
7.9-23.5), neonatal lab-confirmed infection (37 studies,
median prevalence 1.5%, IQR 0.1-7.1), neonatal clinical
signs of infection (8 studies, median prevalence 11.3%,
IQR 4.5-24.9), neonatal lab-confirmed or clinical signs
of infection (8 studies, median prevalence 9.3%, IQR
6.0-16.8), and neonatal colonization (31 studies, median
prevalence 7.3%, IQR 3.8-17.3). Ten studies defined
maternal exposures or neonatal outcomes in categories
that were too heterogeneous to place in a meta-analysis
[8-17].
Regional
Available data on laboratory cultures, clinical signs,
colonization status, and risk factors varied by region.
The Americas, Europe and western Pacific regions had
studies that examined maternal lab-confirmed, clinical
signs, colonization, and risk factors. None of the studies
in Africa, the eastern Mediterranean, and southeast Asia
provided lab-confirmed maternal infection data, and no
studies in Africa, the eastern Mediterranean, and the
western Pacific provided clinical signs data. We were able
to find studies in every region with maternal colonization
data and with neonatal lab confirmed infection and
colonization data, with the majority in the Americas and
Europe. There were no studies of neonatal clinical infec-
tion from Africa or the eastern Mediterranean.
Risk of bias
Among the 122 included studies, 10 (8.2%) studies were
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Figure 1 Flow diagram of study selection.
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after considering selection and misclassification biases
(Additional file 5: Figure S1). Eighteen (14.8%) studies
had different eligibility criteria or baseline characteristics
between the exposed and comparison groups. These
studies were at high risk of selection bias. In assessing for
misclassification bias, the majority of studies measured
exposures or outcomes using reliable laboratory based
culture methods. However, 24 (19.6%) studies determined
the exposure from risk factors or clinical signs and 18
(14.7%) studies determined the outcome from clinical
signs of sepsis.Meta-analyses
The meta-analysis results are presented by exposure out-
come combination: (i) maternal infection and neonatal in-
fection; (ii) maternal colonization and neonatal infection;
(iii) maternal colonization and neonatal colonization; and
(iv) maternal risk factors and neonatal clinical infection.
The study characteristics and exposure/outcome defini-
tions for individual study data are shown in the Additional
file 2: Table S2 and Additional file 3: Table S3.Maternal infection and neonatal infection
Thirty-eight studies reported data on maternal infections
and neonatal infections. We excluded five studies from
the meta-analysis: three studies that measured maternal
urinary tract infection exposure, which reported zero to
two percent vertical transmission rates, and two popula-
tion surveillance studies that looked at only at rare infec-
tions such as Listeria species and Bacteriodes species
infections [11,18-21].
In studies where mothers had lab-confirmed infection,
17.2% (95% CI 6.5-27.9) of their newborns were infected
(“lab/lab”) (Figure 2). Of the 11 studies reporting lab-
confirmed maternal infection in the “lab/lab” meta-
analysis, four (36.4%) examined amniotic fluid cultures,
two (18.2%) used blood cultures, two studied blood and/
or amniotic fluid cultures, two tested placental swab cul-
tures, and one (9.1%) detected funisitis by histologic
examination of the umbilical cord. A sensitivity analysis
excluding high risk for bias studies produced a slightly
increased prevalence of 19.5% (95% CI 2.3-36.8).
Similarly, in studies where mothers were diagnosed
with clinical signs of infection, 20.1% (95% CI 8.1-32.1)
of their newborns had lab confirmed infection (“signs/















Total number of studies
(qualitative and meta-analysis)*
122 37 37 39 27
Number of studies in
the meta-analysis*
107 32 36 38 27
Study sample size, median
(25th, 75th percentile)
337 (IQR 144-1413) 146 (IQR 53-524) 937 (IQR 201-2040) 800 (IQR 317-1457) 225 (IQR 94-1280)
Study type
Cohort (including RCTs) 117 (95.9%) 34 (91.9%) 36 (97.3%) 39 (100%) 26 (96.3%)
Nested case-control 2 (1.6%) 1 (2.7%) 1 (2.7%) – 1 (3.7%)
Population surveillance 3 (2.5%) 2 (5.4%) – – –
Location
Health facility 94 (77.0%) 28 (75.7%) 28 (75.7%) 31 (79.5%) 21 (77.8%)
Multi-center 24 (19.7%) 7 (18.9%) 7 (18.9%) 7 (18.0%) 6 (22.2%)
Unknown or not clear 4 (3.3%) 2 (5.4%) 2 (5.4%) 1 (2.6%) –
Urban or rural
Urban or periurban 99 (81.2%) 30 (81.1%) 28 (75.7%) 33 (84.6%) 22 (81.5%)
Mixed 2 (1.6%) 1 (2.7%) – – –
Unknown or not clear 21 (17.2%) 6 (16.2%) 9 (24.3%) 6 (15.4%) 5 (18.5%)
Timing of early-onset sepsis
First seven days of life 75 (61.5%) 18 (48.6%) 24 (64.9%) 31 (79.5%) 15 (55.6%)
Not reported or unclear 47 (38.5%) 19 (51.4%) 13 (35.1%) 8 (20.5%) 12 (44.4)
Antibiotic use
No intrapartum antibiotic use 28 (23.0%) 4 (10.8%) 10 (27.0%) 10 (25.6%) 9 (33.3%)
Some intrapartum antibiotic use 51 (41.8%) 21 (56.8%) 17 (46.0%) 13 (33.3%) 11 (40.7%)
Unknown or not clear 43 (35.2%) 12 (32.4%) 10 (27.0%) 16 (41.0%) 7 (25.9%)
High risk population
Preterm 8 (6.6%) 7 (18.9%) – – 3 (11.1%)
PROM 5 (4.1%) 2 (5.4%) 1 (2.7%) – 4 (14.8%)
PPROM 17 (13.9%) 7 (18.9%) 2 (5.4%) – 8 (29.6%)
Prolonged rupture of membranes 1 (0.8%) – – – 1 (3.7%)
Preterm or PROM 5 (4.1%) 2 (5.4%) 2 (5.4%) 1 (2.6%) 3 (11.1%)
Preterm or PPROM 2 (1.6%) – – – 2 (7.4%)
None, all women included 80 (65.6%) 17 (45.0%) 31 (83.8%) 36 (92.3%) 6 (22.2%)
Other or unclear 4 (3.3%) 2 (5.4%) 1 (2.7%) 2 (5.1%) –
WHO Region
Africa 3 (2.5%) – – 2 (5.1%) 1 (3.7%)
Americans 52 (42.6%) 23 (62.2%) 16 (43.2%) 6 (15.4%) 16 (59.3%)
Eastern Mediterranean 3 (2.5%) – 1 (2.7%) 3 (7.7%) –
Europe 49 (40.2%) 8 (21.6%) 11 (29.7%) 23 (59.0%) 8 (29.6%)
Southeast Asia 5 (4.1%) (5.4%) 3 (8.1%) 2 (5.1%) 1 (3.7%)
Western Pacific 10 (8.2%) 4 (10.8%) 6 (16.2%) 3 (7.7%) 1 (3.7%)
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Table 1 Characteristics of included studies (Continued)
Neonatal mortality range
Very low mortality <5 per
1000 live births
104 (85.2%) 34 (91.9%) 32 (86.5%) 28 (71.8%) 23 (85.2%)
Low mortality 5-14 8 (6.6%) 1 (2.7%) – 6 (15.4%) 2 (7.4%)
High mortality 15-27 3 (2.5%) – 2 (5.4%) 2 (5.1%) –
Very high mortality >27 7 (5.7%) 2 (5.4%) 3 (8.1%) 3 (7.7%) 2 (7.4%)
Income range
High income (≥12276)
per capita in USD
104 (85.3%) 34 (91.9%) 32 (86.5%) 29 (74.4%) 22 (81.5%)
Upper middle income (3976-12275) 11 (9.0%) 1 (2.7%) 1 (2.7%) 7 (18.0%) 3 (11.1%)
Lower middle income (1006-3975) 6 (4.9%) 2 (5.4%) 4 (10.8%) 3 (7.7%) 1 (3.7%)
Low income (≤1005) 1 (0.8%) – – – 1 (3.7%)
*Studies could be included in more than one meta-analysis (Maternal infections and neonatal infections, Maternal colonization and neonatal infections, Maternal
colonization and neonatal colonization, and Maternal risk factors and neonatal infections).
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of infection in the “signs/lab” analysis, four (40.0%)
examined intrapartum fever, two (20.0%) clinical chor-
ioamnionitis, two (20.0%) intra-amnionitic infection,
one (10.0%) intrapartum risk factors, and one (10.0%)
nonspecific clinical infection.
In studies where mothers had lab-confirmed infection,
37.6% (95% CI 27.2-48.0) of their newborns had clinical
signs of infection (“lab/signs”). In studies where mothers
had lab-confirmed infection, 40.0% (95% CI 15.4-64.7) of
their newborns had lab or clinical signs of infection
(“lab/lab&signs”). Sufficient data were not available for the
sensitivity analysis separating studies by antibiotic use.
Maternal colonization and neonatal infection
Thirty-seven studies reported data on maternal colon-
ization and neonatal infections. One study, Craig et al,
was excluded from the meta-analysis as an outlier, as it
reported that 80% of newborns of colonized mothers
were infected [30]. In studies that measured neonatal
infection with lab tests (“colonization/lab”), the prevalence
of neonatal infection among newborns of colonized
mothers was 0% (95% CI 0.0-0.0) (24 studies, median
2.0%, IQR 0.3-4.6) and 0% (95% CI -0.1-0.1) (10 studies,
median 9.6%, IQR 1.8-9.4) in studies that measured neo-
natal infection with clinical signs (“colonization/signs”). In
studies that used lab tests and collected clinical signs of
neonatal infection (“colonization/lab&signs”), 5.0% (95%
CI 1.9-8.2) (7 studies, median 5.6%, IQR 1.8-9.4) of colo-
nized mothers had newborns with infection (Figure 3). A
sensitivity analysis excluding studies with known or pos-
sible antibiotic use showed a slight increase in prevalence
of neonatal infections in studies that tested lab outcomes
(1.1%, 95% CI 0.2-2.0), studies that diagnosed clinical signs
of neonatal infection (6.5%, 95% CI -6.5-19.5), and studies
that collected clinical signs of infection and conducted
labs tests (7.6%, 95% CI 1.4-13.8).Most studies focused on maternal Group B Streptococcus
(GBS) colonization. We conducted meta-analyses by region
of studies that tested maternal GBS colonization and that
measured neonatal infection with lab tests (“colonization/
lab”). In the Americas, 3.2% (95% CI 1.8-4.7) (10 studies,
median 3.0%, IQR 1.6-4.5) of GBS colonized mothers had
newborns with infection. In Europe, 0.2% (95% CI -0.1-0.4)
(4 studies, median 0.4%, IQR 0.2-0.7) of GBS colonized
mothers had newborns with infection. In western Pacific
region, 0.0% (95% CI 0.0-0.0) (2 studies, median 0.0%,
IQR 0.0-0.0) of GBS colonized mothers had newborns
with infection. We did not have sufficient data to con-
duct a sensitivity analysis excluding studies with some
or unknown antibiotic use.
Maternal colonization and neonatal colonization
Thirty-nine studies reported data on maternal colonization
and neonatal colonization (“colonization/colonization”).
We present these results by pathogen-specific subgroups.
In thirty-one studies where mothers were colonized with
GBS, 38.9% (95% CI 29.6-48.2) of the newborns had
surface GBS colonization. In seven studies where mothers
were colonized with Staphylococcus aureus, 39.5% (95%
CI 16.1-63.0) of the newborns had surface S. aureus
colonization. In three studies where mothers were colo-
nized with Escherichia coli, 34.3% (95% CI 4.2-64.5) of the
newborns had E. coli colonization. In three studies where
mothers were colonized with Ureaplasma species, 45.5%
(95% CI 26.4-64.5) of the newborns were colonized with
Ureaplasma species. Two studies did not differentiate
clearly between organisms. In these studies, 30.9% (95%
CI 25.6-87.4) of the newborns were colonized (Figure 4).
Maternal risk factors and neonatal infection
Twenty-seven studies presented data on maternal risk
factors and neonatal infections. All were included in the
meta-analysis. In studies where mothers had prolonged
Figure 2 Maternal infection and neonatal infection [22-53].
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Figure 3 Maternal colonization and neonatal infection [54-86].
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borns had positive lab cultures for infection. In studies
where mothers had PPROM, 8.5% (95% CI 2.9-14.1) of the
newborns had positive lab cultures for infection. In studies
where mothers had PROM or PPROM, 3.5% (95% CI -3.0-
9.9) of newborns had positive lab cultures for infection. In
studies where mothers had PROM, 3.1% (95% CI -2.2-8.4)
of the newborns had positive lab cultures. In studies where
mothers experienced preterm labor, 2.9% (95% CI 1.7-4.2)
of the newborns had positive lab cultures (Figure 5).The prevalence of neonatal infection was higher in
studies that measured neonatal clinical signs of infection
(“risk/signs”). In studies where mothers had preterm
labor, 7.0% (95% CI 1.4-12.6) of the newborns had clinical
signs of infection. In studies where mothers had PROM,
14.1% (95% CI 10.6-17.6) of the newborns had clinical
signs of infection. In studies where mothers had PPROM,
32.1% (95% CI 3.7-60.6) of the newborns had clinical signs
of infection. In studies where mothers had prolonged
rupture of membranes, 18.6% (95% CI 0.4-36.7) of the
Figure 4 Maternal colonization and neonatal colonization [87-114].
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studies that measured neonatal clinical signs or lab tests
(“risk/lab&signs”), the prevalence of neonatal infection
was even higher among newborns born to women with
preterm labor (37.5%, 95% CI -3.1-78.2) or PROM (16.1%,
95% CI 1.3-31.0) although the 95% CIs overlapped with
the studies that measured neonatal clinical signs only.Discussion
We estimate a high prevalence of neonatal infection in
the first seven days of life where mothers had genital
tract infection or risk factors for infection. In studies of
pregnant mothers with laboratory confirmed infection,
17% of their newborns had positive laboratory cultures
for infection. Similarly, in studies of pregnant mothers
Figure 5 Maternal risk factors and neonatal infection [115-127].
Chan et al. BMC Infectious Diseases  (2015) 15:118 Page 11 of 16with clinical signs of infection, 20% of newborns had
positive lab cultures for infection.
We included studies that measured maternal colon-
ization or risk factors for infection. After excluding studies
with known or possible antibiotic use, 1-7% (dependingon definition of infection) of newborns exposed to mater-
nal colonization developed neonatal infections. Most
studies in our review that assessed maternal colonization
examined GBS. Our findings are consistent with a US
based review showing 2.0% of newborns exposed to
Chan et al. BMC Infectious Diseases  (2015) 15:118 Page 12 of 16maternal GBS developed early-onset GBS neonatal sepsis
[128,129]. The lower prevalence of GBS colonization
among newborns exposed to maternal GBS colonization
in Europe compared to the US may be related to regional
differences in GBS strains or a sampling bias in the studies
meeting our inclusion criteria. Approximately 30-45% of
newborns were surface colonized if they were born to a
colonized mother, suggesting a high rate of surface bacter-
ial transmission via direct contact through the birth canal
between the mother and newborn. Pregnant women with
risk factors, particularly PPROM, preterm labor, and pro-
longed rupture of membranes, had a high prevalence of
neonatal infection. These risk factors may lead to bacterial
infections, and may be indications for women to present
to a health facility. In settings where laboratory or clinical
measures are not available, the presence of risk factors
may be a useful target for interventions to prevent early-
onset neonatal sepsis.
Studies with lab tests for neonatal infection provided a
more conservative measure of prevalence than studies
with clinical signs of neonatal infection. The true preva-
lence of neonatal infection is likely to be between the
specific lab-confirmed measures and sensitive clinical
signs measures. Studies with colonization measures were
also dependent on laboratory facilities and these findings
may not be generalizable to populations without such
facilities. Not many studies utilized molecular diagnostic
methods in our review. As PCR-based diagnoses of
maternal and neonatal infections are becoming more
widely used, our ability to detect true neonatal infections
will improve.
More studies are needed to accurately estimate the
prevalence of early-onset neonatal infection in cases where
mothers are infected or colonized, especially in low-
income countries. Among our included studies, there was
no maternal infection data (lab confirmed or clinical signs)
from Africa and the eastern Mediterranean. In southeast
Asia, no studies looked at lab-confirmed maternal infec-
tion and only two studies reported clinical signs of
infection.
Our review has several limitations. Most studies were
assessed to be at high risk or unclear risk of bias, which
introduced systematic differences in baseline characteris-
tics, outcome measurements, and estimates of point
prevalence. We conducted a sensitivity analysis to ex-
clude high risk studies in order to provide less biased
estimates.
Since all studies were facilities-based, mostly concen-
trated in urban settings in the Americas and Europe, we
could not capture the prevalence of early-onset neonatal
sepsis among home births, rural births, or births at com-
munity facilities in lower-income countries, thereby limit-
ing the generalizability of these findings. Included studies
tended to have high prevalence of maternal infections,suggesting that these studies may be more biased towards
pregnant women with more severe disease or risk factors.
Authors are more likely to report positive findings in
international English journals, whereas negative findings
are published in non-English journals. We excluded non-
English articles due to our limited resources. To assess for
publication bias, we used funnel plots of standard error
and prevalence to graph the correlation between the
variance and distribution of effect sizes. Results were not
statistically significant (p = 0.10).
There were limited data available on intrapartum anti-
biotic use in these studies. The majority of studies had
either some or unknown antibiotic use. The inclusion of
pregnant mothers who had received antibiotics would
lead a study to underestimate the vertical transmission
rates that would occur without antibiotic intervention.
There was significant heterogeneity of the prevalence
results included in the meta-analysis because of the
different measures of exposures and outcomes (lab-con-
firmed, clinical signs, colonization, and risk factors). To
minimize heterogeneity, we grouped studies by exposure
and outcome definitions and conducted separate meta-
analyses for each group, although this reduced the number
of studies in each meta-analysis. To account for additional
differences, we used a random-effects model. We did not
provide an overall estimate of vertical transmission across
all studies because we assessed the studies to be too
heterogeneous.
A strength of our study was our comprehensive search
strategy; we included all articles with a measure or raw
data on maternal and neonatal infections or colonization.
Our study is the first to synthesize different measures of
infection and provide prevalence estimates of neonatal
early-onset infection among newborns of women with
infections, colonization, or risk factors. Our findings
highlight the need for better screening and diagnostics
to identify pregnant women with infections and/or
colonization to better understand the population based
prevalence of maternal infections and/or colonization
with common EOS pathogens in LMIC, which if treated
would have the potential to reduce the burden of early-
onset neonatal infections. Additional studies, such as a
randomized controlled trial on the effect of intrapartum
antibiotic prophylaxis on early-onset neonatal sepsis in
low resource settings, are also needed.
Conclusion
This study reinforces the importance of ongoing efforts
in research and policy development to prevent early-
onset neonatal sepsis by targeting pregnant women with
infections (laboratory-confirmed, clinical signs), bacterial
colonization, and risk factors. Standardizing definitions
for maternal infections and newborns would be helpful
to compare studies. High quality studies, with laboratory-
Chan et al. BMC Infectious Diseases  (2015) 15:118 Page 13 of 16confirmed, clinical signs, colonization, and risk factors are
needed in low-resource areas, especially southeast Asia
and Africa.
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